Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
Rang in Aktien #1926
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Aktienkurs
$63.48
Zuletzt synchronisiert: 2024-12-17
Marktkapitalisierung
$11.52B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Catalent, Inc. (CTLT)

Kategorie

Operative Marge für Catalent, Inc. (CTLT)
Operative Marge zum August 2026 TTM: -17.10%
Laut den neuesten Finanzberichten und dem Aktienkurs von Catalent, Inc. beträgt die aktuelle operative Marge (TTM) -17.10%. Am Ende des Jahres 2023 lag die operative Marge bei -3.20%.
Historie der operativen Marge von Catalent, Inc. von 2011 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -17.10% 0.00%
2024 -17.10% 434.38%
2023 -3.20% -144.26%
2022 7.23% -18.31%
2021 8.85% 90.32%
2020 4.65% 89.80%
2019 2.45% -77.75%
2018 11.01% -2.39%
2017 11.28% -4.33%
2016 11.79% -16.97%
2015 14.20% 7.74%
2014 13.18% 16.12%
2013 11.35% -2.83%
2012 11.68% -3.87%
2011 12.15% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -101.34%
IN
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.